These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 8050210

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG, Fischer ER, Harris DC.
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [Abstract] [Full Text] [Related]

  • 3. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
    Icardi A, Paoletti E, Molinelli G.
    Adv Perit Dial; 1990 Mar; 6():292-5. PubMed ID: 1982830
    [Abstract] [Full Text] [Related]

  • 8. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C, Blumberg A.
    Schweiz Med Wochenschr; 1990 Feb 17; 120(7):217-20. PubMed ID: 2309110
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr 17; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Apr 17; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A, Malagoli A, Komninos G, Pastori G.
    J Nephrol; 2002 Apr 17; 15(5):565-74. PubMed ID: 12455725
    [Abstract] [Full Text] [Related]

  • 14. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N, Osman-Malik Y, Frinak S, Besarab A.
    Am J Kidney Dis; 2006 Apr 17; 47(4):644-54. PubMed ID: 16564942
    [Abstract] [Full Text] [Related]

  • 15. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ, Kent AB, Becker GJ, McMahon LP.
    Nephrology (Carlton); 2004 Jun 17; 9(3):153-60. PubMed ID: 15189176
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 17; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 19. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
    Galliford JW, Malasana R, Farrington K.
    Nephrol Dial Transplant; 2005 Sep 17; 20(9):1956-62. PubMed ID: 15930017
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.